Stifel analyst Paul Matteis maintains $Neurogene (NGNE.US)$ with a buy rating, and adjusts the target price from $44 to $46.
According to TipRanks data, the analyst has a success rate of 39.5% and a total average return of 2.2% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Neurogene (NGNE.US)$'s main analysts recently are as follows:
The stock is currently trading "near cash" following the company's disclosure of a Serious Adverse Event in its NGN-401 high dose trial, along with the termination of the Battens program. Despite these issues, management does not anticipate a clinical hold after discussions with the FDA, noting the safety of the low-dose treatment.
The revised outlook for the shares reflects a model update for the third quarter of 2024 and considerations regarding the status of a trial participant who was critically affected after receiving a high dose of NGN-401. The adjustment in expectations also accounts for a reduced forecast of the market share for the Rett syndrome gene therapy, specifically NGN-401, now estimated at 50%.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
